Gene Editing Market By Technology (Zinc Finger Nucleases (ZFNs), Transcription Activator-Like Effector-based Nucleases (TALENs), CRISPR-Cas9 Gene Editing, Restriction Enzymes, Others), By Application (Gene editing, Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Drug development, Others), By End User (Biotechnology and Pharmaceutical Companies, Academic and Government Research Institutes, Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global gene editing market was valued at $3,886.34 million in 2021, and is projected to reach $7,437.47 million by 2031, registering a CAGR of 6.7% from 2022 to 2031.
Gene editing (also known as genome editing) refers to a set of technologies that allows scientists to alter an organism's DNA. These technologies allow for the addition, removal, or modification of genetic material at specific points in the genome. There have been several ways to develop genome editing. CRISPR-Cas9, which stands for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9, is one of the most well-known techniques. The CRISPR-Cas9 system has sparked a lot of interest in the scientific community as it is faster, cheaper, more accurate, and more efficient than existing genome editing approaches. CRISPR-Cas9 is based on a naturally occurring genome editing technology used by bacteria to defend themselves. When bacteria are infected with viruses, they capture small fragments of the virus's DNA and insert them into their own DNA in a specific way to form CRISPR arrays. Bacteria can remember viruses, thanks to CRISPR arrays (or closely related ones). If the viruses resurface, the bacteria create RNA segments from CRISPR arrays that detect and attach to specific sections of the viruses' DNA. The bacteria then employ Cas9 or a similar enzyme to rip the virus's DNA apart, rendering it inoperable. This immune defense mechanism was modified to modify DNA by researchers. They make a small piece of RNA with a short guide sequence that connects (binds) to a specific target sequence in a cell's DNA, similar to the RNA segments produced by bacteria using the CRISPR array. This guide RNA binds to the Cas9 enzyme as well. When the guide RNA is injected into cells, it detects the desired DNA sequence, and the Cas9 enzyme cuts the DNA at the desired position, similar to how bacteria do it. Although Cas9 is the most commonly employed enzyme, other enzymes (such as Cpf1) can also be used. Researchers employ the cell's own DNA repair mechanism to add or delete portions of genetic material, or to make modifications after the DNA has been cut.
Factors such as increased adoption of CRISPR genome editing technology along with expanding synthetic gene demand in various biotechnology areas has fueled the growth of the gene editing market. Furthermore, due to the growing uses of genome editing technologies, the industry is seeing increased competition among market competitors. The highly flexible CRISPR technique has gotten a lot of attention lately. For example, Vertex Pharmaceuticals paid CRISPR Therapeutics $900 million in April 2021 to develop, manufacture, and market CRISPR-Cas9 gene-edited treatment for beta-thalassemia and sickle-cell disease. Market growth is expected to be aided by such activities. Furthermore, the industry is being driven by the development of CRISPR-based innovative diagnostic tools to alleviate the negative effects of the COVID-19 pandemic.
The gene editing market is segmented on the basis of technology, application, end user, and region. On the basis of technology, the market is bifurcated into zinc finger nucleases, transcription activator-like effector-based, crispr-cas9 gene editing, restriction enzymes, and others. The others segment is further classified into homing endonucleases or meganucleases and antisense technology. By application, the market is segmented into gene editing, cell line engineering, animal genetic engineering, plant genetic engineering, drug development, and others. The others segment is further classified into bioenergy, diagnosis, cell and gene therapies, microorganisms genetic engineering, drug discovery, gmo (genetically modified organisms), vaccine development, and basic research. By end users, the market is fragmented into biotechnology & pharmaceutical companies, academic & government research institutes, and contract research organizations
Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Major key players that operate in the global gene editing market are Addgene, Allele Biotech, Bio-Rad Laboratories, CRISPR Therapeutics, General Electric, OriGene Technologies, Precision Biosciences, Takara Biotech, Thermofischer Scientific Inc., and Transposagen Biopharma Inc.
Key Benefits For Stakeholders
This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the gene editing market analysis from 2021 to 2031 to identify the prevailing gene editing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the gene editing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global gene editing market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Technology
Zinc Finger Nucleases (ZFNs)
CRISPR-Cas9 Gene Editing
Restriction Enzymes
Others
Transcription Activator-Like Effector-based Nucleases (TALENs)
By Application
Drug development
Others
Gene editing
Cell Line Engineering
Animal Genetic Engineering
Plant Genetic Engineering
By End User
Biotechnology and Pharmaceutical Companies
Academic and Government Research Institutes
Contract Research Organizations
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Addgene
Allele Biotech
Bio-Rad
Takara Bio
CRISPR Therapeutics
OriGene Technologies
Precision Biosciences
GE Healthcare
Merck KGaA
ThermoFischer Scientific Inc.
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: GENE EDITING MARKET, BY TECHNOLOGY
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Zinc Finger Nucleases (ZFNs)
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Transcription Activator-Like Effector-based Nucleases (TALENs)
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 CRISPR-Cas9 Gene Editing
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Restriction Enzymes
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Others
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: GENE EDITING MARKET, BY APPLICATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Gene editing
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Cell Line Engineering
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Animal Genetic Engineering
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Plant Genetic Engineering
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Drug development
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- 5.7 Others
- 5.7.1 Key market trends, growth factors and opportunities
- 5.7.2 Market size and forecast, by region
- 5.7.3 Market analysis by country
- CHAPTER 6: GENE EDITING MARKET, BY END USER
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Biotechnology and Pharmaceutical Companies
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Academic and Government Research Institutes
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Contract Research Organizations
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- CHAPTER 7: GENE EDITING MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Technology
- 7.2.3 North America Market size and forecast, by Application
- 7.2.4 North America Market size and forecast, by End User
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Technology
- 7.2.5.1.2 Market size and forecast, by Application
- 7.2.5.1.3 Market size and forecast, by End User
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Technology
- 7.2.5.2.2 Market size and forecast, by Application
- 7.2.5.2.3 Market size and forecast, by End User
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Technology
- 7.2.5.3.2 Market size and forecast, by Application
- 7.2.5.3.3 Market size and forecast, by End User
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Technology
- 7.3.3 Europe Market size and forecast, by Application
- 7.3.4 Europe Market size and forecast, by End User
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Technology
- 7.3.5.1.2 Market size and forecast, by Application
- 7.3.5.1.3 Market size and forecast, by End User
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Technology
- 7.3.5.2.2 Market size and forecast, by Application
- 7.3.5.2.3 Market size and forecast, by End User
- 7.3.5.3 U.K.
- 7.3.5.3.1 Market size and forecast, by Technology
- 7.3.5.3.2 Market size and forecast, by Application
- 7.3.5.3.3 Market size and forecast, by End User
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Technology
- 7.3.5.4.2 Market size and forecast, by Application
- 7.3.5.4.3 Market size and forecast, by End User
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Technology
- 7.3.5.5.2 Market size and forecast, by Application
- 7.3.5.5.3 Market size and forecast, by End User
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Technology
- 7.3.5.6.2 Market size and forecast, by Application
- 7.3.5.6.3 Market size and forecast, by End User
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Technology
- 7.4.3 Asia-Pacific Market size and forecast, by Application
- 7.4.4 Asia-Pacific Market size and forecast, by End User
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Technology
- 7.4.5.1.2 Market size and forecast, by Application
- 7.4.5.1.3 Market size and forecast, by End User
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Technology
- 7.4.5.2.2 Market size and forecast, by Application
- 7.4.5.2.3 Market size and forecast, by End User
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Technology
- 7.4.5.3.2 Market size and forecast, by Application
- 7.4.5.3.3 Market size and forecast, by End User
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Technology
- 7.4.5.4.2 Market size and forecast, by Application
- 7.4.5.4.3 Market size and forecast, by End User
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Technology
- 7.4.5.5.2 Market size and forecast, by Application
- 7.4.5.5.3 Market size and forecast, by End User
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Technology
- 7.4.5.6.2 Market size and forecast, by Application
- 7.4.5.6.3 Market size and forecast, by End User
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Technology
- 7.5.3 LAMEA Market size and forecast, by Application
- 7.5.4 LAMEA Market size and forecast, by End User
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Technology
- 7.5.5.1.2 Market size and forecast, by Application
- 7.5.5.1.3 Market size and forecast, by End User
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Technology
- 7.5.5.2.2 Market size and forecast, by Application
- 7.5.5.2.3 Market size and forecast, by End User
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Technology
- 7.5.5.3.2 Market size and forecast, by Application
- 7.5.5.3.3 Market size and forecast, by End User
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Technology
- 7.5.5.4.2 Market size and forecast, by Application
- 7.5.5.4.3 Market size and forecast, by End User
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Addgene
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Allele Biotech
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Bio-Rad
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Takara Bio
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 CRISPR Therapeutics
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 OriGene Technologies
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 Precision Biosciences
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 GE Healthcare
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Merck KGaA
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 ThermoFischer Scientific Inc.
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 2. GENE EDITING MARKET SIZE, FOR ZINC FINGER NUCLEASES (ZFNS), BY REGION, 2021-2031 ($MILLION)
- TABLE 3. GENE EDITING MARKET FOR ZINC FINGER NUCLEASES (ZFNS) BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. GENE EDITING MARKET SIZE, FOR TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR-BASED NUCLEASES (TALENS), BY REGION, 2021-2031 ($MILLION)
- TABLE 5. GENE EDITING MARKET FOR TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR-BASED NUCLEASES (TALENS) BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. GENE EDITING MARKET SIZE, FOR CRISPR-CAS9 GENE EDITING, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. GENE EDITING MARKET FOR CRISPR-CAS9 GENE EDITING BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. GENE EDITING MARKET SIZE, FOR RESTRICTION ENZYMES, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. GENE EDITING MARKET FOR RESTRICTION ENZYMES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. GENE EDITING MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. GENE EDITING MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 13. GENE EDITING MARKET SIZE, FOR GENE EDITING, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. GENE EDITING MARKET FOR GENE EDITING BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. GENE EDITING MARKET SIZE, FOR CELL LINE ENGINEERING, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. GENE EDITING MARKET FOR CELL LINE ENGINEERING BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. GENE EDITING MARKET SIZE, FOR ANIMAL GENETIC ENGINEERING, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. GENE EDITING MARKET FOR ANIMAL GENETIC ENGINEERING BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. GENE EDITING MARKET SIZE, FOR PLANT GENETIC ENGINEERING, BY REGION, 2021-2031 ($MILLION)
- TABLE 20. GENE EDITING MARKET FOR PLANT GENETIC ENGINEERING BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 21. GENE EDITING MARKET SIZE, FOR DRUG DEVELOPMENT, BY REGION, 2021-2031 ($MILLION)
- TABLE 22. GENE EDITING MARKET FOR DRUG DEVELOPMENT BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 23. GENE EDITING MARKET SIZE, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
- TABLE 24. GENE EDITING MARKET FOR OTHERS BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 25. GLOBAL GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 26. GENE EDITING MARKET SIZE, FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. GENE EDITING MARKET FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. GENE EDITING MARKET SIZE, FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. GENE EDITING MARKET FOR ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 30. GENE EDITING MARKET SIZE, FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021-2031 ($MILLION)
- TABLE 31. GENE EDITING MARKET FOR CONTRACT RESEARCH ORGANIZATIONS BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 32. GENE EDITING MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 33. NORTH AMERICA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 34. NORTH AMERICA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 35. NORTH AMERICA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 36. NORTH AMERICA GENE EDITING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 37. U.S. GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 38. U.S. GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 39. U.S. GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 40. CANADA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 41. CANADA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 42. CANADA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 43. MEXICO GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 44. MEXICO GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 45. MEXICO GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 46. EUROPE GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 47. EUROPE GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 48. EUROPE GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 49. EUROPE GENE EDITING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 50. GERMANY GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 51. GERMANY GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 52. GERMANY GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 53. FRANCE GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 54. FRANCE GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 55. FRANCE GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 56. U.K. GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 57. U.K. GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 58. U.K. GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 59. ITALY GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 60. ITALY GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 61. ITALY GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 62. SPAIN GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 63. SPAIN GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 64. SPAIN GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 65. REST OF EUROPE GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 66. REST OF EUROPE GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 67. REST OF EUROPE GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 70. ASIA-PACIFIC GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 71. ASIA-PACIFIC GENE EDITING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 72. JAPAN GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 73. JAPAN GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 74. JAPAN GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 75. CHINA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 76. CHINA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 77. CHINA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 79. AUSTRALIA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 80. AUSTRALIA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 81. INDIA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 82. INDIA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 83. INDIA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 85. SOUTH KOREA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 86. SOUTH KOREA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 88. REST OF ASIA-PACIFIC GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 89. REST OF ASIA-PACIFIC GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 90. LAMEA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 91. LAMEA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 92. LAMEA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 93. LAMEA GENE EDITING MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 95. BRAZIL GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 96. BRAZIL GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 98. SAUDI ARABIA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 99. SAUDI ARABIA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 101. SOUTH AFRICA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 102. SOUTH AFRICA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA GENE EDITING MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 104. REST OF LAMEA GENE EDITING MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 105. REST OF LAMEA GENE EDITING MARKET, BY END USER, 2021-2031 ($MILLION)
- TABLE 106.ADDGENE: COMPANY SNAPSHOT
- TABLE 107.ADDGENE: OPERATING SEGMENTS
- TABLE 108.ADDGENE: PRODUCT PORTFOLIO
- TABLE 109.ADDGENE: NET SALES,
- TABLE 110.ADDGENE: KEY STRATERGIES
- TABLE 111.ALLELE BIOTECH: COMPANY SNAPSHOT
- TABLE 112.ALLELE BIOTECH: OPERATING SEGMENTS
- TABLE 113.ALLELE BIOTECH: PRODUCT PORTFOLIO
- TABLE 114.ALLELE BIOTECH: NET SALES,
- TABLE 115.ALLELE BIOTECH: KEY STRATERGIES
- TABLE 116.BIO-RAD: COMPANY SNAPSHOT
- TABLE 117.BIO-RAD: OPERATING SEGMENTS
- TABLE 118.BIO-RAD: PRODUCT PORTFOLIO
- TABLE 119.BIO-RAD: NET SALES,
- TABLE 120.BIO-RAD: KEY STRATERGIES
- TABLE 121.TAKARA BIO: COMPANY SNAPSHOT
- TABLE 122.TAKARA BIO: OPERATING SEGMENTS
- TABLE 123.TAKARA BIO: PRODUCT PORTFOLIO
- TABLE 124.TAKARA BIO: NET SALES,
- TABLE 125.TAKARA BIO: KEY STRATERGIES
- TABLE 126.CRISPR THERAPEUTICS: COMPANY SNAPSHOT
- TABLE 127.CRISPR THERAPEUTICS: OPERATING SEGMENTS
- TABLE 128.CRISPR THERAPEUTICS: PRODUCT PORTFOLIO
- TABLE 129.CRISPR THERAPEUTICS: NET SALES,
- TABLE 130.CRISPR THERAPEUTICS: KEY STRATERGIES
- TABLE 131.ORIGENE TECHNOLOGIES: COMPANY SNAPSHOT
- TABLE 132.ORIGENE TECHNOLOGIES: OPERATING SEGMENTS
- TABLE 133.ORIGENE TECHNOLOGIES: PRODUCT PORTFOLIO
- TABLE 134.ORIGENE TECHNOLOGIES: NET SALES,
- TABLE 135.ORIGENE TECHNOLOGIES: KEY STRATERGIES
- TABLE 136.PRECISION BIOSCIENCES: COMPANY SNAPSHOT
- TABLE 137.PRECISION BIOSCIENCES: OPERATING SEGMENTS
- TABLE 138.PRECISION BIOSCIENCES: PRODUCT PORTFOLIO
- TABLE 139.PRECISION BIOSCIENCES: NET SALES,
- TABLE 140.PRECISION BIOSCIENCES: KEY STRATERGIES
- TABLE 141.GE HEALTHCARE: COMPANY SNAPSHOT
- TABLE 142.GE HEALTHCARE: OPERATING SEGMENTS
- TABLE 143.GE HEALTHCARE: PRODUCT PORTFOLIO
- TABLE 144.GE HEALTHCARE: NET SALES,
- TABLE 145.GE HEALTHCARE: KEY STRATERGIES
- TABLE 146.MERCK KGAA: COMPANY SNAPSHOT
- TABLE 147.MERCK KGAA: OPERATING SEGMENTS
- TABLE 148.MERCK KGAA: PRODUCT PORTFOLIO
- TABLE 149.MERCK KGAA: NET SALES,
- TABLE 150.MERCK KGAA: KEY STRATERGIES
- TABLE 151.THERMOFISCHER SCIENTIFIC INC.: COMPANY SNAPSHOT
- TABLE 152.THERMOFISCHER SCIENTIFIC INC.: OPERATING SEGMENTS
- TABLE 153.THERMOFISCHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
- TABLE 154.THERMOFISCHER SCIENTIFIC INC.: NET SALES,
- TABLE 155.THERMOFISCHER SCIENTIFIC INC.: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.GENE EDITING MARKET SEGMENTATION
- FIGURE 2.GENE EDITING MARKET,2021-2031
- FIGURE 3.GENE EDITING MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.GENE EDITING MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.GENE EDITING MARKET,BY TECHNOLOGY,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF ZINC FINGER NUCLEASES (ZFNS) GENE EDITING MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR-BASED NUCLEASES (TALENS) GENE EDITING MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CRISPR-CAS9 GENE EDITING GENE EDITING MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF RESTRICTION ENZYMES GENE EDITING MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHERS GENE EDITING MARKET,2021-2031(%)
- FIGURE 18.GENE EDITING MARKET,BY APPLICATION,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF GENE EDITING GENE EDITING MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF CELL LINE ENGINEERING GENE EDITING MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF ANIMAL GENETIC ENGINEERING GENE EDITING MARKET,2021-2031(%)
- FIGURE 22.COMPARATIVE SHARE ANALYSIS OF PLANT GENETIC ENGINEERING GENE EDITING MARKET,2021-2031(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF DRUG DEVELOPMENT GENE EDITING MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF OTHERS GENE EDITING MARKET,2021-2031(%)
- FIGURE 25.GENE EDITING MARKET,BY END USER,2021(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES GENE EDITING MARKET,2021-2031(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF ACADEMIC AND GOVERNMENT RESEARCH INSTITUTES GENE EDITING MARKET,2021-2031(%)
- FIGURE 28.COMPARATIVE SHARE ANALYSIS OF CONTRACT RESEARCH ORGANIZATIONS GENE EDITING MARKET,2021-2031(%)
- FIGURE 29.GENE EDITING MARKET BY REGION,2021
- FIGURE 30.U.S. GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 31.CANADA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 32.MEXICO GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 33.GERMANY GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 34.FRANCE GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 35.U.K. GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 36.ITALY GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 37.SPAIN GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 38.REST OF EUROPE GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 39.JAPAN GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 40.CHINA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 41.AUSTRALIA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 42.INDIA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 43.SOUTH KOREA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 44.REST OF ASIA-PACIFIC GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 45.BRAZIL GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 46.SAUDI ARABIA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 47.SOUTH AFRICA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 48.REST OF LAMEA GENE EDITING MARKET,2021-2031($MILLION)
- FIGURE 49. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 50. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 51. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 52.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 53.COMPETITIVE DASHBOARD
- FIGURE 54.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 55.ADDGENE.: NET SALES ,($MILLION)
- FIGURE 56.ALLELE BIOTECH.: NET SALES ,($MILLION)
- FIGURE 57.BIO-RAD.: NET SALES ,($MILLION)
- FIGURE 58.TAKARA BIO.: NET SALES ,($MILLION)
- FIGURE 59.CRISPR THERAPEUTICS.: NET SALES ,($MILLION)
- FIGURE 60.ORIGENE TECHNOLOGIES.: NET SALES ,($MILLION)
- FIGURE 61.PRECISION BIOSCIENCES.: NET SALES ,($MILLION)
- FIGURE 62.GE HEALTHCARE.: NET SALES ,($MILLION)
- FIGURE 63.MERCK KGAA.: NET SALES ,($MILLION)
- FIGURE 64.THERMOFISCHER SCIENTIFIC INC..: NET SALES ,($MILLION)
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook